Edition:
United States

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

10.29USD
14 Dec 2017
Change (% chg)

$-0.16 (-1.53%)
Prev Close
$10.45
Open
$10.45
Day's High
$11.14
Day's Low
$10.05
Volume
6,430
Avg. Vol
7,377
52-wk High
$16.59
52-wk Low
$7.95

Summary

Name Age Since Current Position

Frank Armstrong

60 2013 Non-Executive Chairman of the Board

Glyn Edwards

59 2012 Chief Executive Officer, Executive Director

Erik Ostrowski

42 2014 Chief Financial Officer

David Roblin

2017 Chief Operating Officer, President - Research and Development

Ralf Rosskamp

63 2015 Chief Medical Officer

Valerie Andrews

55 2014 Non-Executive Director

Stephen Davies

64 2013 Non-Executive Director

Barry Price

71 2013 Non-Executive Director

David Wurzer

2015 Non-Executive Director

Leopoldo Zambeletti

2014 Non-Executive Director

Richard Pye

Director of Corporate Communications

Biographies

Name Description

Frank Armstrong

Dr. Frank Murdoch Armstrong is the Non-Executive Chairman of the Board of Summit Therapeutics Plc since June 2013. Prior to this, Dr Armstrong led Medical Science and Innovation at Merck Serono, the biopharmaceutical division of Merck KGaA, from 2010 to 2011. Dr Armstrong was also Head of Worldwide Product Development at Bayer AG from 1998 to 2001 and held various positions at ICI plc and Zeneca plc, now AstraZeneca plc, from 1985 to 1988. Dr Armstrong has served as the Chief Executive Officer at five biotechnology companies, including Fulcrum Pharma, CuraGen, which was acquired by Celldex Therapeutics Inc, Bioaccelerate, Provensis and Phoqus. Dr Armstrong is the Non-Executive Chairman of the Boards of Directors of Xceleron Ltd, Cardiorentis AG and RedX Pharma plc. He is a Non-Executive Director on the Boards of Actino Pharma and Juniper Pharmaceuticals Inc (formerly Columbia Laboratories Inc), which is listed on NASDAQ, and a Member of the Strategic Advisory Board of HealthCare Royalty Partners, and a Senior Advisor at Phase 4 Partners. Dr Armstrong received an honours degree in Biochemistry and an MBChB in Medicine from the University of Edinburgh in Scotland. Dr Armstrong is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow of the Faculty of Pharmaceutical Physicians.

Glyn Edwards

Mr. Glyn Edwards is Chief Executive Officer, Executive Director of Summit Corporation plc., since 4 April 2012. Mr. Edwards has a wealth of experience garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles. Prior to joining Summit, he was interim Chief Executive Officer of the UK trade body the BioIndustry Association (BIA) and Chief Executive Officer at Antisoma plc for 13 years, and Vice President of Business Development at Therapeutic Antibodies Ltd. Mr. Edwards holds a BSc in Biochemistry from Bristol University and an MSc in Economics from the London Business School.

Erik Ostrowski

Mr. Erik Ostrowski was appointed the Company’s Chief Financial Officer in June 2014. Prior to joining Summit, Erik was the Vice President of Finance of biotechnology company, Organogenesis. He also had a successful career in healthcare investment banking, most recently with Leerink Partners. Erik works out of the Company’s US office.

David Roblin

Dr. David Roblin is Chief Operating Officer, President - Research and Development of the Company, since June 2017. Dr. Roblin was Interim Chief Operating Officer, President - Research and Development, since April 2017. Dr David Roblin has had an extensive and highly successful career in the life sciences industry. Dr Roblin held senior leadership roles at Pfizer and Bayer where he was involved in research, development and commercialisation. At Pfizer, he was Head of Research, Site Director and CMO for Europe R&D and he and his units were responsible for the development of several important and successful medicines. At Bayer, he was Head of Therapy Area for Anti-infectives where he was involved in the successful development of a number of antibiotics, including Avelox™ and Cipro™. In 2014 Dr Roblin was appointed COO and Director of Scientific Translation at the Francis Crick Institute in London where he led on establishing the operations of a new biomedical research institute at a purpose built state-of-the-art research facility in central London. On stepping down from his full-time roles, Dr Roblin will become a Senior Scientific Translation Fellow and Chair of the Translation Advisory Group at the Francis Crick Institute. Dr Roblin has been Chief Medical Officer and a Non-Executive Director to a number of biotech companies. He also serves on the Major Awards Committee of the Biomedical Catalyst Fund and of the Confidence in Concept and Proximity to Discovery of Medical Research Council. He also serves on the LEO Foundation Prize Committee. Dr Roblin has a degree in biochemistry from University College London and later qualified in medicine from St George's Hospital. He is a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George's. He is a Board Director of MedCity and Destiny Pharma. Before entering the life sciences industry,

Ralf Rosskamp

Dr. Ralf H. Rosskamp, M.D. is Chief Medical Officer of the Company. Dr Rosskamp brings to Summit broad drug development and regulatory expertise from his career in the biotechnology industry. He has been responsible for numerous investigational new drug applications, the design and execution of clinical development programs, and new drug applications across multiple therapeutic areas including rare diseases. Dr Rosskamp has been involved in the approval of a number of products including Amaryl®, Lantus®, Apidra®, Simcor®, and most recently the FDA authorisation of Natpara® for the treatment of a rare endocrine disease called hypoparathyroidism. Prior to joining NPS Pharmaceuticals, which was subsequently acquired by Shire Pharmaceuticals, he was Executive Vice President, R&D at rare disease specialist Ikaria. Dr Rosskamp has also served as Executive Vice President, R&D of Kos Pharmaceuticals (acquired by Abbott Labs), Vice President, Global Therapeutic Area Endocrinology, Metabolism, Rheumatology and Bone at Aventis Pharmaceuticals and Head, Clinical Research - Metabolism and Global Clinical Director, Recombinant Products at Hoechst AG. In his academic career, Dr Rosskamp served as Associate Professor, Pediatric Endocrinology in the Department of Pediatrics at the University of Bonn. He received his MD in pediatrics from the University of Bonn.

Valerie Andrews

Ms. Valerie L. Andrews is Non-Executive Director of Summit Therapeutics plc. Ms. Andrews served as the General Counsel for Vertex Pharmaceuticals Inc until May 2014. Prior to joining Vertex in 2002, she was an Executive Director of Licensing for Massachusetts General and The Brigham and Women's Hospitals in Boston, and a partner in the Boston law firm Hill & Barlow. She served as a law clerk to the Chief Judge Levin H Campbell of the US Court of Appeals for the First Circuit from 1988 to 1989. Ms Andrews has also been a Non-Executive Director of the drug development company Columbia Laboratories since 2005. Ms Andrews is a member of the Massachusetts Bar, and holds a JD in law (Boston College) and a BA in chemistry and psychology (Duke University).

Stephen Davies

Professor Stephen Davies serves as Non-Executive Director of Summit Corporation Plc. He co-founded Summit in January 2003. He was Chairman of Summit until September 2006 and guided the Company through a flotation and the formative years of the Company’s development. In 1992, Prof. Davies founded the spin-out companies Oxford Asymmetry and Oxford Diversity which later combined for the IPO of Oxford Asymmetry International. This merged in 2000 with Evotec for £316 million. He has been professor at Oxford University for 20 years and was elected to the Waynflete Chair of Chemistry in 2006, one of the prestigious academic posts in UK science. In addition, Prof. Davies has received awards for his contribution to organic chemistry. Prof. Davies holds directorships with Isis Innovations Ltd and Sci-ink Ltd.

Barry Price

Dr. Barry J. Price, Ph.D., is Non-Executive Director of Summit Corporation Plc since June 2013. He has a wealth of industry and boardlevel expertise in the pharmaceutical and life sciences industry. He spent 28 years with the Glaxo Group of companies and held several executive positions including Managing Director of Glaxochem Ltd. Dr. Price was a Non-Executive Director of Shire plc and during his 13 years with the company, he was involved in Shire developing into one of the UK’s largest and most successful life science companies. Dr. Price was appointed Non-Executive Chairman of Summit in 2006 and has previously held directorships at Chiroscience plc, Celltech Group plc, Pharmagene plc, Antisoma plc and BioWisdom Ltd.

David Wurzer

Mr. David M. Wurzer CPA, has been appointed as Non-Executive Director of Summit Therapeutics Plc., with effect from 23 February 2015. He has extensive experience in business and financial matters relating to the pharmaceutical and biotechnology sector having held a number of senior executive and board level positions. Mr Wurzer was Executive Vice President, Treasurer and Chief Financial Officer of the NASDAQ listed biotechnology company CuraGen Corporation from 1997 to 2008. He also held a number of positions at Value Health Inc., from 1991 to 1997 including Senior Vice President, Treasurer and Chief Financial Officer. He is currently the Executive Vice President and Chief Investment Officer at Connecticut Innovations, a state funded venture capital fund. Mr. Wurzer is currently a Non-Executive Director on the boards of Response Genetics and Special Diversified Opportunities, Inc., and from 2010 to 2012 he was a Non-Executive Director on the board of DUSA Pharmaceuticals. Mr. Wurzer is a Certified Public Accountant and began his career with Coopers & Lybrand, which is now part of PricewaterhouseCoopers. He received a BBA from the University of Notre Dame.

Leopoldo Zambeletti

Mr. Leopoldo Zambeletti has been appointed as Non-Executive Director of Summit Corporation PLC., with effect from 30 May 2014. Mr Zambeletti is an independent strategic advisor to the life sciences sector with expertise in a range of areas including mergers and acquisitions, equity financing and product out-licensing. Mr Zambeletti previously worked in investment banking for 19 years where he led the European Healthcare Investment teams at JP Morgan and Credit Suisse respectively. He is a highly respected figure within the life sciences sector. During a 19 year career as an investment banker, he led the European Healthcare Investment team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. Since 2013 Mr Zambeletti has been an independent strategic advisor to life science companies on Merger and Acquisitions, out-licensing deals and financing strategy. He is a Non-Executive Director of Nogra Pharma and an advisor to the US medtech company Qardio. He serves as a trustee to Barts and the London Charity, which helps to fund the hospitals of the Barts NHS Trust including St Bartholomew, the Royal London and the London Chest Hospitals, and he is a founder of the cultural initiative 5x15 Italy. Mr Zambeletti started his career at KPMG as an accountant.

Richard Pye

Basic Compensation